Beryl A. Hatton

Maxygen (United States)

Papers

1

Total Citations

5

H-Index

1

About

Beryl A. Hatton is a translational oncology researcher whose work focuses on the intersection of interventional oncology and immunotherapy, with a particular emphasis on novel ablation technologies for metastatic disease. Her most cited paper, “The Safety of Pulsed Electric Field Ablation Before Standard of Care Treatment for Patients With Metastatic Cancer” (2025, 5 citations), evaluates the safety of Aliya pulsed electric field (PEF) ablation in lung lesions performed concurrently with diagnostic biopsy, prior to first-line standard of care therapy. This work addresses a critical gap in the management of metastatic cancer by exploring whether non-thermal ablation can be safely integrated into early treatment pathways without delaying or compromising systemic therapy. Hatton’s research contributes to the growing field of image-guided, minimally invasive interventions that may enhance local tumor control while preserving immune function. Her findings help establish safety benchmarks for combining PEF ablation with conventional treatments, potentially paving the way for larger efficacy trials. Through this work, Hatton is advancing the clinical translation of pulsed electric field technology, offering new possibilities for patients with metastatic disease who have limited treatment options.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
The Safety of Pulsed Electric Field Ablation Before Standard of Care Treatment for Patients With Metastatic Cancer
5 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Maxygen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago